Sun Pharma Buys Its Way Into the $3.7 Billion PCSK9 Market: What the Lerodalcibep Licensing Deal Adds
- September 28, 2026
- Posted by: Harsh Piplani
- Category: News
Sun Pharma lerodalcibep rights outside US and China. EU approved 21 Sep. Market $3.7bn ex-US and China, 38% CAGR. Stock near Rs 1,847, P/E 36.7 vs industry 38.4.
Quick Answer
The Sun Pharma lerodalcibep deal is an exclusive licence to commercialise and manufacture the once-monthly cholesterol drug worldwide, excluding the United States and China, signed with LIB Therapeutics. The drug is approved in the EU as Lyrokaul and targets a PCSK9 inhibitor market of $3.7 billion outside the US and China that is growing at 38 percent a year. Financial terms are confidential beyond an upfront payment, milestones and royalties to LIB, so the shares reacted little, trading near Rs 1,847.
Sun Pharmaceutical Industries and LIB Therapeutics announced an exclusive licensing agreement on 28 September for lerodalcibep, a PCSK9 inhibitor that lowers LDL cholesterol. Sun Pharma gets rights to commercialise and manufacture the drug across every market except the United States and China, and it will be responsible for obtaining regulatory approvals in licensed territories where the drug is not yet approved.
LIB will receive an upfront payment, future milestone payments and royalties on net sales in the licensed territories. Other terms are confidential, which limits how far investors can model the impact, but the deal adds a cardiovascular product to the company’s innovative medicines portfolio at a point when the drug has just cleared its most important approval.
Click Here – Get Free Investment Predictions
The Drug: What Lerodalcibep Is
Lerodalcibep is a fusion protein that binds PCSK9, a protein that breaks down the liver’s LDL receptors. By blocking it, the drug increases the number of receptors available to clear LDL cholesterol from the blood. It is given as a once-monthly 300 mg subcutaneous injection in a prefilled syringe and, according to the companies, can be stored at ambient temperature in the EU for six months.
The European Medicines Agency’s committee gave a positive opinion on 23 July 2026, and the drug received EU approval on 21 September as Lyrokaul for adults with hypercholesterolaemia and mixed dyslipidaemia. Its late-stage LIBerate programme enrolled more than 2,900 patients across studies.
Also read – Stocks to Watch Today: PB Fintech, Mazagon Dock, More
Sun Pharma Lerodalcibep Deal: The Market Opportunity
The companies estimate the PCSK9 market outside the US and China at $3.7 billion, growing at 38 percent a year, within a global market approaching $7 billion in 2026. Sun Pharma’s managing director said once-monthly dosing, a small injection volume and six-month ambient storage simplify treatment and offer convenience over existing options.
A drug that is already approved lets Sun Pharma skip the earlier and riskier stages of development. Its work is now regulatory filings in markets beyond the EU, building a commercial presence and managing supply, since Sun also holds manufacturing rights.
Sun Pharma Lerodalcibep Deal: Can the Balance Sheet Fund It?
Sun Pharma reported first-quarter FY27 consolidated net profit up 27.08 percent to Rs 2,894.8 crore, with adjusted net profit of Rs 3,089.4 crore, driven by 16 percent growth in India formulation sales. Debt-to-equity is only 0.06, so the company can fund upfront and milestone payments from internal cash without straining its balance sheet.
That strength is what allows the company to in-license late-stage assets. Buying a product that is already approved is faster and less costly than discovering one.
Check Live Prices, RSI and Fundamentals on Univest Screener
Sun Pharma Share Price and Valuation
| Metric | Value |
|---|---|
| Pre-open price | Rs 1,842.30, down 0.60% from Rs 1,853.50 |
| Later price | About Rs 1,847 |
| Market capitalisation | Rs 4,44,717 crore |
| P/E ratio | 36.70 vs industry 38.42 |
| Return on equity | 13.74% |
| Debt-to-equity | 0.06 |
| RSI (14-day) | 38.9 |
| SuperTrend (bearish) resistance | Rs 1,929.6 |
| 20-day average | Rs 1,876.5 |
The stock traded slightly lower in the pre-open session and remained near its previous close, which shows that investors did not attach a large near-term earnings effect to a deal whose financial terms are not disclosed. Technically, it remains below its 20-day average and SuperTrend resistance, so the chart, not the news, is driving the price.
Also read – Intraday Stocks for Today: 3 Setups From Vikran, Divi’s Labs and Olectra
Risks and What to Watch
- Launch and reimbursement: pricing and reimbursement negotiations in Europe and other markets can take time and vary by country.
- Competition: existing injectable PCSK9 therapies and new oral LDL-lowering drugs such as obicetrapib, which received a positive EU committee opinion in July, compete for the same patients.
- Regulatory filings: Sun Pharma must secure approvals in licensed territories beyond the EU.
- Cost: upfront and milestone payments could weigh on margins before sales ramp up, and the amounts are undisclosed.
Download the Univest iOS App or Univest Android App to track live prices, corporate announcements and price alerts for the stocks in this story.
Conclusion
The Sun Pharma lerodalcibep deal adds a once-monthly cholesterol drug to its cardiovascular portfolio at a moment when the drug has just won EU approval, and it targets a market that the companies estimate at $3.7 billion outside the US and China. Financial terms are confidential and the stock barely moved, so the deal is a strategic addition and not yet an earnings event. Track the company’s filings and its price levels on the Univest Screener.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data independently before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the Sun Pharma lerodalcibep deal?
Ans. Sun Pharma has an exclusive licence from LIB Therapeutics to commercialise and manufacture lerodalcibep worldwide, excluding the United States and China.
What is lerodalcibep?
Ans. Lerodalcibep is a once-monthly PCSK9 inhibitor that lowers LDL cholesterol, approved in the EU as Lyrokaul on 21 September 2026.
How big is the market behind the Sun Pharma lerodalcibep deal?
Ans. The companies estimate the PCSK9 market outside the US and China at $3.7 billion, growing at 38 percent a year, within a global market of about $7 billion in 2026.
What will LIB Therapeutics receive?
Ans. LIB will receive an upfront payment, future milestone payments and royalties on net sales in the licensed territories, and other terms are confidential.
How did the Sun Pharma share price react?
Ans. The stock traded at Rs 1,842.30 in the pre-open session, down 0.60 percent, and later moved near Rs 1,847, so the reaction was small.
What is Sun Pharma’s valuation?
Ans. Sun Pharma trades at 36.70 times earnings against an industry multiple of 38.42, with return on equity of 13.74 percent and debt-to-equity of 0.06.
What are the main risks of the Sun Pharma lerodalcibep deal?
Ans. The risks include reimbursement negotiations, competition from existing and new therapies, the need for regulatory approvals in more markets, and undisclosed upfront and milestone costs.
